| Name | Title | Contact Details |
|---|
The Place for Children with Autism provides a comprehensive approach to autism treatment that focuses on the highest quality therapy to enrich the lives of children with autism and their families across all communities. Utilizing one-to-one ABA therapy in a structured, center-based environment, our programs are designed with quality as the priority and support as the ongoing means to achieve it. We specialize in all developmental areas to help children build independence and school readiness skills to succeed. The Place for Children with Autism works with families from all economic backgrounds to find options that fit their needs.
Colonial Manors Of Custer is a Custer, SD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Art & Drama Therapy Institute is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Augusta Medical Systems, LLC was formed in 1999 and its owner, Michael Osbon, has a long history in office based urological products for the treatment of Erectile Dysfunction. Augusta Medical Systems was formed not only to deliver the best Vacuum
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic